<DOC>
	<DOCNO>NCT01246895</DOCNO>
	<brief_summary>This follow-up study evaluate effect BST-CarGel® application microfractured lesion ( investigational ) microfracture alone ( control ) 5 year treatment subject , treat Protocols CG-CIP01-P CG-CIP02-P , serve post approval study Protocols , support commercial application . The lesion treat Protocols CG-CIP01-P CG-CIP02-P focal lesion articular cartilage , grade 3 4 ( either ICRS Outerbridge classification ) medial lateral femoral condyle knee , classify either acute chronic .</brief_summary>
	<brief_title>Follow-Up Study Comparing BST-CarGel Microfracture Repair Articular Cartilage Lesions Knee</brief_title>
	<detailed_description>Cartilage repair currently remain problematic orthopedic concern effective solution . The development new surgical technique therapy critical meeting medical need . Clinical data regard long-term durability repair tissue result cartilage repair technique microfracture , autologous chondrocyte implantation mosaicplasty lacking . Only two study , one comparative one uncontrolled , examine long-term repair outcome ( 4 year ) . These study reinforce concept study need identify technique product lead long-term clinical benefit improved cartilage repair efficacy . BST-CarGel® medical device derive chitosan apply microfractured lesion show promote quantity quality cartilage repair tissue animal . The efficacy safety BST-CarGel® currently evaluate human compare standard care treatment , microfracture , 12 month international study Canada , Europe Korea Protocols CG-CIP01-P CG-CIP02-P . When protocol design carry , BST-CarGel® technology belong BioSyntech Canada Inc . Afterwards , technology acquire Piramal Healthcare ( Canada ) Ltd. owner technology sponsor Extension Study CG-C1P04 . This follow-up study evaluate long-term effect ( 5 yr ) BST-CarGel® + microfracture microfracture alone subject treated pivotal sub-studies . All eligible subject ( maximum 80 ) treat Protocols CG-CIP01-P CG-CIP02-P complete required 12 month follow-up period ask participate follow-up study . The stratification Protocols CG-CIP01-P CG-CIP02-P ( investigational site lesion type ) retain purpose follow-up study , third party MRI central reading facility remain blinded treatment receive Protocols CG-CIP01-P CG-CIP02-P . Comparisons two treatment group perform . The following assessment do annually year 3 and/or 4 5 post -treatment Protocols CG-CIP01-P CG-CIP02-P subject treat BST-CarGel + microfracture microfracture alone : 1 . Analyses tissue repair carry base degree lesion fill quality repair tissue use MRI 2 . The general health status subject capture case report form ( CRF ) include subject 's overall health status , treat knee status , adverse event ( AEs ) concomitant medication . 3 . The assessment subject 's knee pain , stiffness , functional ability quality life self-assessment questionnaire ( Western Ontario McMaster Universities osteoarthritis index ( WOMAC ) short-form-36 ( SF-36v2 )</detailed_description>
	<criteria>The subject treat Protocol CGCIP01 CGCIP02 complete 12 month followup period The subject understood sign Research Ethics Board ( REB ) approve Informed Consent Form ( ICF ) The subject treat Protocol CGCIP01P CGCIP02P The subject complete 12 month followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Cartilage repair</keyword>
	<keyword>Cartilage</keyword>
	<keyword>Knee</keyword>
	<keyword>Knee Injuries</keyword>
	<keyword>Knee Pain</keyword>
	<keyword>Microfracture</keyword>
	<keyword>Bone Marrow Stimulation</keyword>
	<keyword>Arthroscopy</keyword>
</DOC>